Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Rigel Pharmaceuticals
RIGL
Rigel Pharmaceuticals
Patent Risks And Regulatory Pressures Will Limit Oncology Promise
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
18 Jul 25
Updated
18 Jul 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$20.45
10.9% overvalued
intrinsic discount
18 Jul
US$22.67
Loading
1Y
157.6%
7D
13.4%
Author's Valuation
US$20.5
10.9% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$20.5
10.9% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-93m
259m
2014
2017
2020
2023
2025
2026
2028
Revenue US$258.7m
Earnings US$10.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
8.27%
Biotech revenue growth rate
10.61%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.59%
Calculation
US$10.13m
Earnings '28
x
44.19x
PE Ratio '28
=
US$447.59m
Market Cap '28
US$447.59m
Market Cap '28
/
18.73m
No. shares '28
=
US$23.90
Share Price '28
US$23.90
Share Price '28
Discounted to 2025 @ 6.73% p.a.
=
US$19.65
Fair Value '25
